These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 19527090

  • 1. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract] [Full Text] [Related]

  • 2. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC.
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 4. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Li H, Zhang X.
    N Engl J Med; 2010 May 06; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
    [No Abstract] [Full Text] [Related]

  • 5. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM.
    N Engl J Med; 2010 Feb 04; 362(5):456-8. PubMed ID: 20089958
    [No Abstract] [Full Text] [Related]

  • 6. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr 04; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 7. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP, Weissert R.
    Clin Neuropharmacol; 2011 Apr 04; 34(1):28-35. PubMed ID: 21242742
    [Abstract] [Full Text] [Related]

  • 8. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
    Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, FORTE Study Group.
    Ann Neurol; 2011 Jan 04; 69(1):75-82. PubMed ID: 21280077
    [Abstract] [Full Text] [Related]

  • 9. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T, Torkildsen Ø, Myhr KM.
    Expert Opin Pharmacother; 2017 Oct 04; 18(15):1627-1635. PubMed ID: 28858531
    [Abstract] [Full Text] [Related]

  • 10. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M.
    Expert Opin Pharmacother; 2013 Jan 04; 14(1):123-36. PubMed ID: 23256518
    [Abstract] [Full Text] [Related]

  • 11. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
    Tselis A.
    Curr Opin Investig Drugs; 2010 May 04; 11(5):577-85. PubMed ID: 20419604
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z.
    Acta Neurol Scand; 2004 Jun 04; 109(6):390-2. PubMed ID: 15147461
    [Abstract] [Full Text] [Related]

  • 13. Cladribine. Ortho Biotech Inc.
    Tortorella C, Rovaris M, Filippi M.
    Curr Opin Investig Drugs; 2001 Dec 04; 2(12):1751-6. PubMed ID: 11892941
    [Abstract] [Full Text] [Related]

  • 14. Cladribine for multiple sclerosis: review and current status.
    Sipe JC.
    Expert Rev Neurother; 2005 Nov 04; 5(6):721-7. PubMed ID: 16274330
    [Abstract] [Full Text] [Related]

  • 15. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL.
    Value Health; 2019 Jul 04; 22(7):772-776. PubMed ID: 31277823
    [Abstract] [Full Text] [Related]

  • 16. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A, Montalban X.
    Expert Rev Neurother; 2008 May 04; 8(5):699-714. PubMed ID: 18457527
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.
    Mult Scler; 2019 May 04; 25(6):819-827. PubMed ID: 29716436
    [Abstract] [Full Text] [Related]

  • 18. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
    Schmidt S.
    Nervenarzt; 2010 Oct 04; 81(10):1231-41. PubMed ID: 20567960
    [Abstract] [Full Text] [Related]

  • 19. [Therapeutic indications targeting etiology. (With the exception of primary progressive forms)].
    Brassat D.
    Rev Neurol (Paris); 2001 Sep 04; 157(8-9 Pt 2):1014-28. PubMed ID: 11787332
    [Abstract] [Full Text] [Related]

  • 20. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb 04; 56(2):21-24. PubMed ID: 29449328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.